What is MinervaX?
MinervaX is a clinical-stage biotech firm dedicated to creating novel vaccines, with a primary focus on Group B Streptococcus (GBS). Their lead candidate, AlpN GBS, is engineered for administration to pregnant women and older adults, aiming to prevent adverse pregnancy outcomes and severe infections. The company's mission is to tackle significant gaps in current medical interventions. With a substantial capital infusion, MinervaX is poised to advance its clinical trials and bring its innovative vaccine solutions closer to market.
How much funding has MinervaX raised?
MinervaX has raised a total of $199.5M across 4 funding rounds:
Series A
$8.7M
Series B
$57.6M
Private Equity
$76.5M
Other Financing Round
$56.7M
Series A (2014): $8.7M with participation from Sunstone and Lauritzen Fonden
Series B (2020): $57.6M led by Novo Holdings, LF Investment, Industrifonden, Adjuvant Capital, Wellington Partners, Sunstone Life Science Ventures, and Sanofi Ventures
Private Equity (2022): $76.5M supported by Trill Impact Ventures, Pureos Bioventures, REPAIR Impact Fund, and Sunstone Life Science Ventures
Other Financing Round (2023): $56.7M featuring OrbiMed, Sanofi Ventures, Pureos Bioventures, EQT Group, and Novo Holdings
Key Investors in MinervaX
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise across the healthcare sector, including biopharmaceuticals and medical devices. The firm manages capital for companies at various stages of development, from early-stage ventures to established organizations scaling proven healthcare solutions.
Sanofi Ventures
Sanofi Ventures is the corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with innovative products and technologies of strategic interest to Sanofi, particularly in oncology, immunology, rare diseases, and vaccines.
Pureos Bioventures
Pureos Bioventures is a venture capital firm that invests in private companies focused on developing innovative therapeutics, particularly in biological drugs and drug formats, aiming to improve patient outcomes for severe diseases.
What's next for MinervaX?
The substantial enterprise-level funding and recent strategic investment indicate MinervaX is in a scaling phase, likely Series B or beyond, enabling robust progression through clinical development. This capital injection will be crucial for advancing AlpN GBS through rigorous clinical trials, potentially leading to regulatory submissions and commercialization. The company's focus on GBS prevention addresses a significant global health concern, positioning MinervaX for potential market leadership in maternal and adult vaccination.
See full MinervaX company page
